Glioblastoma multiforme: a review of where we have been and where we are going.
about
Identification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaBrain tumor stem cells: Molecular characteristics and their impact on therapyNovel delivery strategies for glioblastomaTherapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International ConsortiumTargeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene ConsortiumAdult brain cancer in the U.S. black population: a Surveillance, Epidemiology, and End Results (SEER) analysis of incidence, survival, and trendsTranslational validation of personalized treatment strategy based on genetic characteristics of glioblastomaIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsGenomic estimates of aneuploid content in glioblastoma multiforme and improved classificationDiacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.Enhancing drug delivery for boron neutron capture therapy of brain tumors with focused ultrasoundPseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.Salvage therapy with single agent bendamustine for recurrent glioblastoma.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Neural stem cell therapy for cancer.Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of gliomaA ten-microRNA expression signature predicts survival in glioblastomaStructural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure.Pharmacokinetic interactions with antiepileptic drugs: always the bad actor or simply misunderstood?Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters."Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy.Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner.Master regulators, regulatory networks, and pathways of glioblastoma subtypes.The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levelsLong-term survival with primary glioblastoma multiforme: a clinical study in bulgarian patients.Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Economics of Malignant Gliomas: A Critical Review.A pseudogene-signature in glioma predicts survival.Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier PermeabilityCalpain 2 is required for the invasion of glioblastoma cells in the zebrafish brain microenvironment.Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastomaFungal metabolite ophiobolin A as a promising anti-glioma agent: In vivo evaluation, structure-activity relationship and unique pyrrolylation of primary amines.Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomideWittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines
P2860
Q24612429-5797BE21-A714-4264-B34D-8E34C42E033AQ27003138-1EB77BDC-0308-4FA1-8B4F-06E9192CC029Q27006099-C9B7867C-C116-4782-A3B2-4B780EAD642DQ27333831-6EBABF73-D80A-41A9-82A2-F8FF583024C9Q28383443-9AAA99D8-9016-470C-A801-51CA3BDF3025Q28387326-DA8737B5-ECFB-4E17-ADA6-D04EF49C9F49Q28393814-25EE905D-0B04-4F7E-ADCB-5FEBFE95D2C2Q28541502-11758E64-8C30-4BEC-8D4C-EAB5EC93EAF4Q28544645-9DA9DF16-A5F3-4C14-9AF1-31B8AA97DF67Q28716240-0707E5AE-6837-4008-AACA-80019FA244D2Q30412090-CEBC4460-F9B6-4065-A5D4-7546608E01FEQ30423722-1980B64B-CE4F-46E2-BB5B-5C57E00969CAQ30432022-C89A2B91-9125-47C4-AD22-4306669A4C1DQ30617625-4053D168-247C-4758-8518-DFC7271BE350Q30843565-5AC95BF1-F36A-46FE-9F28-120941AC7FF5Q33395579-0338B99D-4C19-4E34-A986-F8552C3BA1EAQ33591658-D61BE799-A0A2-4C10-AA2F-EB944EA1B434Q33704489-977F1DF2-D042-4D4B-A08C-72B8FB9941D5Q33734403-6DE20A65-A13E-43F2-B532-414EBC2C505EQ33869822-DCEE757E-F4C9-492C-8808-566B7E195ADBQ33922203-12B74934-1758-4574-B68E-67B92259223EQ34183961-5EE4D5E9-6F6C-47C8-B3E1-A39E5649C39DQ34286305-EE401AEF-E4A9-43F6-9DE6-B85D9D03ED77Q34360907-D5012035-63F8-45CC-A897-43443BAE58F4Q34419969-10553A0B-465E-4D8E-A318-04FCA333D873Q34427910-16BB06CF-B0DA-4932-B968-60E30EBC0830Q34688196-6112EDB2-F9B5-43A6-BF35-3345EE45CCEFQ34712254-76B5F880-9B47-47D6-BB82-D0576A257EA2Q34892346-E2357A45-7F2D-4B84-8FDA-1ECA07B0FF64Q34943946-FC0B68DA-5C7B-4B8D-87D2-DA4D16285D83Q34968951-93E7CBDC-3063-47BB-8ACC-872E04F5A26EQ35191597-94C092FD-2E86-479A-9AAD-839E452D0EA6Q35251878-A61D604B-DDA7-4458-871D-02D158389FDFQ35630252-72FCBEA0-80D7-4ECF-82A9-1F5162107186Q35742619-645857E5-BB16-4992-B3F2-B89A186FA30DQ35970661-E56F15E1-68F7-48D1-98BB-865AB7EE5932Q36119458-37F0F9DE-34D0-4506-81CD-75DD68347441Q36136128-2EF44CE9-13E6-4531-BE4C-454A2B10B51FQ36148612-17F4DD57-2DE6-4461-8A6F-970FE2E5F202Q36198988-E4A94731-4266-40DC-943B-C3541AC29B13
P2860
Glioblastoma multiforme: a review of where we have been and where we are going.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glioblastoma multiforme: a review of where we have been and where we are going.
@en
Glioblastoma multiforme: a review of where we have been and where we are going.
@nl
type
label
Glioblastoma multiforme: a review of where we have been and where we are going.
@en
Glioblastoma multiforme: a review of where we have been and where we are going.
@nl
prefLabel
Glioblastoma multiforme: a review of where we have been and where we are going.
@en
Glioblastoma multiforme: a review of where we have been and where we are going.
@nl
P2093
P1476
Glioblastoma multiforme: a review of where we have been and where we are going.
@en
P2093
Ankit I Mehta
Austin K Mattox
Chunhui Di
Cory Adamson
Ningjing Lin
Okezie O Kanu
P304
P356
10.1517/13543780903052764
P407
P577
2009-08-01T00:00:00Z